Study Association of CA15-3, CEA with Vitamin D3 in Patients Suffering from Breast cancer
DOI:
https://doi.org/10.46966/msjar.v5i3.211Keywords:
Vitamin D3, Breast Cancer, CA15-3, CEA, Tumor MarkersAbstract
Background: The study aims to determine the relationship between CEA and CA15-3 with Vitamin D3 among breast cancer patients. purpose: The study aims to explore the relationship between CEA and CA15-3 with Vitamin D3 in breast cancer patients and hypothesizes that Vitamin D3 may influence these biomarkers related to cancer prognosis. Methods: Conducted at the National Oncology Teaching Hospital in Najaf Governorate from September 2023 to March 2024, the study included 90 breast cancer patients and 90 controls. Serum levels of CA15-3, CEA, and Vitamin D3 were measured using ELISA, with statistical analysis performed using SPSS version 25. Results: The study found significant negative correlations between Vitamin D3 levels and the biomarkers CEA (r = -.422, p = .001) and CA15-3 (r = -.499, p = .001). Breast cancer patients had significantly lower Vitamin D3 levels (9.22 ± 0.07 ng/mL) than controls (35.62 ± 0.02 ng/mL, p = .0001). CA15-3 and CEA levels were significantly higher in patients compared to controls. Implications The findings suggest that Vitamin D3 may regulate tumor markers, impacting breast cancer outcomes and therapy. This supports the potential use of Vitamin D3 supplementation in breast cancer treatment. Conclusion: our study indicated that the level of Vitamin D3 was inversely related to both CEA and CA15-3 whereby a high level of Vitamin D3 corresponded to the low level of these tumor markers This investigation highlights the need to ensure required Vitamin D3 levels in these patients with breast cancer and indicates that administration of Vitamin D3 could be a promising intervention strategy in the management of the Breast Cancer.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 MOHAMMED HADI
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
